VANESSA PINTER: Open Payments
NPI 1891140042 · FLOYD, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$738 in 45 payments from 13 companies in 2025. Trend: 2023 $799 · 2024 $566 · 2025 $738
Food & beverage: $738
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $221 |
| Novo Nordisk Inc | 7 | $133 |
| Amgen Inc. | 7 | $115 |
| Alkermes, Inc. | 3 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $45 |
| PFIZER INC. | 2 | $36 |
| Gilead Sciences, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $19 |
Products named: VRAYLAR, OTEZLA, Ozempic, VIVITROL, Wegovy, ELIQUIS, QULIPTA, AIRSUPRA.
Industry payments across VA — which companies pay providers there.
